Flexibility and responsiveness characterize successful long-term protocols
Dual inhibition of MPC and GDH proves synthetically lethal in glioblastoma, lung, and renal cancers [15]
Cagrilintide, the second generation (2020s) Novo Nordisk took the Pramlintide concept and applied the same half-life extension strategy that they used with Semaglutide: Kept the proline substitutions (anti-amyloid) Added a C20 fatty diacid via a -Glu linker to a lysine residue, albumin binding Additionally stabilized the N- and C-terminal positions Result: Cagrilintide with a half-life of 6.6 days (vs 50 minutes for Pramlintide)
doi: 10.3389/fnut.2021.784354 Received 27 September 2021 Accepted 27 October 2021 Published 22 November 2021 Volume 8 - 2021 Edited by Annalisa Terranegra, Sidra Medicine, Qatar Reviewed by Guoyuan Qi, University of Arizona, United States
The riskbenefit assessment for wellness or anti-aging interventions may differ substantially from that applied to disease-specific therapeutic indications, given the differing clinical objectives and risk tolerances